Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease

Open Medicine (Poland)

Volumn 13, Issue 1, 2018, Pages 402-409

  Miyake, Teruki ^a   Yoshida, Sakiko ^b   Furukawa, Shinya ^a,c   Sakai, Takenori ^d   Tada, Fujimasa ^e   Senba, Hidenori ^a   Yamamoto, Shin ^a   Koizumi, Yohei ^a   Yoshida, Osamu ^a   Hirooka, Masashi ^a   Kumagi, Teru ^a   Niiya, Tetsuju ^b   Miyaoka, Hiroaki ^e   Masanori, Abe ^a   Matsuura, Bunzo ^a   Hiasa, Yoichi ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Matsuyama Shimin Hospital   (Japan)

^c EHIME UNIVERSITY HOSPITAL   (Japan)

^d Yawatahama City General Hospital   (Japan)

^e Saiseikai Matsuyama Hospital   (Japan)

Author keywords

Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Selective sodium glucose cotransporter 2 inhibitor; Ipragliflozin; Type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C; IPRAGLIFLOZIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE LEVEL; BODY COMPOSITION; BODY FAT; BODY WEIGHT LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ECHOGRAPHY; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER INJURY; LIVER PROTECTION; LIVER STIFFNESS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; TRANSIENT ELASTOGRAPHY; TREATMENT DURATION;

EID: 85054614373     PISSN: None     EISSN: 23915463     Source Type: Journal    
DOI: 10.1515/med-2018-0059     Document Type: Article

References (37)

1. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al., Nonalcoholic fatty liver, steatohepatitis, the metabolic syndrome, Hepatology, 2003, 37, 917-923, doi: 10.1053/jhep.2003.50161
2. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., et al., Nonalcoholic fatty liver disease: A feature of the metabolic syndrome, Diabetes, 2001, 50, 1844-1850.
3. Sanyal A.J., AGA technical review on nonalcoholic fatty liver disease, Gastroenterology, 2002, 123, 1705-1725
4. Yoshioka Y., Hashimoto E., Yatsuji S., Kaneda H., Taniai M., Tokushige K., et al., Nonalcoholic steatohepatitis: Cirrhosis, hepatocellular carcinoma, burnt-out NASH, J. Gastroenterol., 2004, 39, 1215-1218
5. Shimada M., Hashimoto E., Taniai M., Hasegawa K., Okuda H., Hayashi N., et al., Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis, J. Hepatol., 2002, 37, 154-160
6. Ochi H., Hirooka M., Koizumi Y., Miyake T., Tokumoto Y., Soga Y., et al., Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases, Hepatology, 2012, 56, 1271-1278, doi: 10.1002/hep.25756
7. de Lédinghen V., Vergniol J., Capdepont M., Chermak F., Hiriart J.B., Cassinotto C., et al., Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations, J. Hepatol., 2014, 60, 1026-1031, doi: 10.1016/j.jhep.2013.12.018
8. Imajo K., Kessoku T., Honda Y., Tomeno W., Ogawa Y., Mawatari H., et al., Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography, Gastroenterology, 2016, 150, 626-637, doi: 10.1053/j. gastro.2015.11.048
9. Chen J., Talwalkar J.A., Yin M., Glaser K.J., Sanderson S.O., Ehman R.L., Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography, Radiology, 2011, 259, 749-756, doi: 10.1148/radiol.11101942
10. Hirooka M., Koizumi Y., Miyake T., Ochi H., Tokumoto Y., Tada F., et al., Nonalcoholic fatty liver disease: Portal hypertension due to outflow block in patients without cirrhosis, Radiology, 2015, 274, 597-604, doi: 10.1148/radiol.14132952
11. Gliši T.M., Periši M.D., Dimitrijevic S., Juriši V., Doppler assessment of splanchnic arterial flow in patients with liver cirrhosis: Correlation with ammonia plasma levels and MELD score, J. Clin. Ultrasound, 2014, 42, 264-269, doi: 10.1002/jcu.22135
12. Promrat K., Kleiner D.E., Niemeier H.M., Jackvony E., Kearns M., Wands J.R., et al., Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis, Hepatology, 2010, 51, 121-129, doi: 10.1002/hep.23276
13. Singh S., Khera R., Allen A.M., Murad M. H., Loomba R., Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis, Hepatology, 2015, 62, 1417-1432, doi: 10.1002/hep.27999
14. Chao E.C., Henry R.R., SGLT2 inhibition-a novel strategy for diabetes treatment, Nat. Rev. Drug Discov., 2010, 9, 551-559, doi: 10.1038/nrd3180
15. Wilding J.P., Ferrannini E., Fonseca V.A., Wilpshaar W., Dhanjal P., Houzer A., Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: A dose-finding study, Diabetes Obes. Metab., 2013, 15, 403-409, doi: 10.1111/dom.12038
16. Komiya C., Tsuchiya K., Shiba K., Miyachi Y., Furuke S., Shimazu N., et al., Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction, PLoS One, 2016, 11, e0151511, doi: 10.1371/journal.pone.0151511
17. Uchida J., Kabeya Y., Oikawa Y., Tanaka H., Atsumi Y., Osawa M., et al., The Ameliorating Effect of Ipragliflozin, a SGLT2 Inhobitor, on Liver Function Without Dependence on the Body Weight Reduction, J. Japan Diab. Soc., 2016, 59, 782-790, doi: 10.11213/tonyobyo.59.782
18. Takase T., Nakamura A., Miyoshi H., Yamamoto C., Atsumi T., Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: An association with glucoselowering effects, Endocr. J., 2017, 64, 363-367, doi: 10.1507/endocrj.EJ16-0295
19. Ohta A., Kato H., Ishii S., Sasaki Y., Nakamura Y., Nakagawa T., et al., Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes, Expert Opin. Pharmacother., 2017, 18, 1433-1438, doi: 10.1080/14656566.2017.1363888
20. Ohki T., Isogawa A., Toda N., Tagawa K., Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors, Clin. Drug Investig., 2016, 36, 313-319, doi: 10.1007/s40261-016-0383-1
21. Ito D., Shimizu S., Inoue K., Saito D., Yanagisawa M., Inukai K., et al., Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial, Diabetes Care, 2017, 40, 1364-1372, doi: 10.2337/dc17-0518
22. Seko Y., Sumida Y., Tanaka S., Mori K., Taketani H., Ishiba H., et al., Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus, Hepatol. Res., 2017, 47, 1072-1078, doi: 10.1111/hepr.12834
23. Tobita H., Sato S., Miyake T., Ishihara S., Kinoshita Y., Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study, Curr. Ther. Res. Clin. Exp., 2017, 87, 13-19, doi: 10.1016/j.curtheres.2017.07.002
24. Akuta N., Watanabe C., Kawamura Y., Arase Y., Saitoh S., Fujiyama S., et al., Effects of a Sodium-Glucose Cotransporter 2 Inhibitor in Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus: Preliminary Prospective Study Based On Serial Liver Biopsies, Hepatol. Commun., 2017, 1, 46-52, doi: 10.1002/hep4.1019
25. Tahara A., Kurosaki E., Yokono M., Yamajuku D., Kihara R., Hayashizaki Y., et al., Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, obesity in type 2 diabetic mice, Eur. J. Pharmacol., 2013, 715, 246-255, doi: 10.1016/j.ejphar.2013.05.014
26. Tahara A., Kurosaki E., Yokono M., Yamajuku D., Kihara R., Hayashizaki Y., et al., Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats, J. Pharm. Pharmacol., 2014, 66, 975-987, doi: 10.1111/jphp.12223
27. Yokono M., Takasu T., Hayashizaki Y., Mitsuoka K., Kihara R., Muramatsu Y., et al., SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats, Eur. J. Pharmacol., 2014, 727, 66-74
28. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., et al., The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, the American Gastroenterological Association, Hepatology, 2012, 55, 2005-2023, doi: 10.1002/hep.25762
29. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J., Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity, Gastroenterology, 1999, 116, 1413-1419.
30. Rafiq N., Bai C., Fang Y., Srishord M., McCullough A., Gramlich T., et al., Long-term follow-up of patients with nonalcoholic fatty liver, Clin. Gastroenterol. Hepatol., 2009, 7, 234-238, doi: 10.1016/j.cgh.2008.11.005
31. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., Bacon B.R., Non-alcoholic steatohepatitis: A proposal for grading and staging the histological lesions, Am. J. Gastroenterol., 1999, 94, 2467-2474
32. Kojima S., Watanabe N., Numata M., Ogawa T., Matsuzaki S., Increase in the prevalence of fatty liver in Japan over the past 12 years: Analysis of clinical background, J. Gastroenterol., 2003, 38, 954-961
33. Sandrin L., Fourquet B., Hasquenoph J.M., Yon S., Fournier C., Mal F., et al., Transient elastography: A new noninvasive method for assessment of hepatic fibrosis, Ultrasound Med. Biol., 2003, 29, 1705-1713
34. Teramoto T., Sasaki J., Ueshima H., Egusa G., Kinoshita M., Shimamoto K., et al., Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese, J. Atheroscler. Thromb., 2007, 14, 155-158
35. Ogihara T., Kikuchi K., Matsuoka H., Fujita T., Higaki J., Horiuchi M., et al., The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009), Hypertens. Res., 2009, 32, 3-107
36. Honda Y., Imajo K., Kato T., Kessoku T., Ogawa Y., Tomeno W., et al., The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice, PLoS One, 2016, 11, e0146337, doi: 10.1371/journal. pone.0146337
37. Jojima T., Tomotsune T., Iijima T., Akimoto K., Suzuki K., Aso Y., Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes, Diabetol. Metab. Syndr., 2016, 8, 45, doi: 10.1186/s13098-016-0169-x